Dr Miri Halperin Wernli is a senior pharmaceutical and biomedical executive with over 25 years of strategic and operational leadership in the biopharmaceutical industry and a deep understanding of drug and product development.
Dr Halperin Wernli has held worldwide senior leadership positions in product development, R&D and strategic marketing throughout Switzerland and in the US (Merck, Sharp and Dohme, Roche and Actelion pharmaceuticals).
Dr Halperin Wernli is an experienced pharmaceutical leader with skills and broad expertise in drug development, regulatory affairs, project & portfolio management, development finance & controlling, corporate strategy and governance. Her extensive pharmaceutical industry and biomed research and development experience covers the full spectrum of areas and activities from pre-clinical to clinical development & strategy, to drug registration and launch, across several therapeutic areas.
|
NEW ROLE: Strategic Advisor, Melodiol Global Health | 06 Sep 2021 |
|
|
NEW ROLE: Non-Executive Director, Melodiol Global Health | 06 Sep 2021 |
|
|
REMUNERATION UPDATE: Co-Founder, Group Chief Executive, Executive Director, Head of Technology, Innovation & Distribution, Melodiol Global Health | 03 Nov 2020 |
| Position | Company | Year | Company's current rank | WA staff |
|---|---|---|---|---|
Strategic Advisor
|
2021 |
